Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. Curis, Inc. (CRIS) Stock Analysis & News | Seeking Alpha Get breaking news and analysis on Curis, Inc. (CRIS) stock, price quote and chart, trading and investing tools. Home - Curis, Inc About Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. We currently have three drug candidates in development: Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with … Curis, Inc. Common Stock (CRIS) Stock Quotes | Nasdaq
CRIS Curis Inc. — Stock Price and Discussion | Stocktwits Apr 03, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. CRIS: Curis Inc - Stock Price, Quote and News - CNBC Get Curis Inc (CRIS:NASDAQ) real-time stock quotes, news and financial information from CNBC.
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it TradingView UK. View live CURIS INC chart to track its stock's price action. Find market predictions, CRIS financials and market news. Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948 12 Mar 2020 (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced Curis is a Lexington, Massachusetts biotechnology company focused on the development Curis shares soar after the biotech executes a reverse stock split. Get today's Stocks & Shares prices, charts, news, top index prices & stock market recommendations. The latest information & more with interactive investor 31 Dec 2019 It looks like hedge funds own 9.0% of Curis shares. That's interesting, because hedge funds can be quite active and activist. Many look for
Why I Sold Curis Inc (NASDAQ:CRIS) – Simply Wall St News Mar 31, 2018 · Curis Inc (NASDAQ:CRIS) is a company I’ve been following for a while, and one that I believe the market is over-hyped about.My concerns are mainly around the sustainability of its future growth, the opportunity cost of investing in the stock accounting for the returns I could have gotten in other peers, and its cash-to-debt management. Curis: Time To Bet On A Courageous Choice - Curis, Inc ... Mar 20, 2018 · Curis plans to provide a regulatory update about CUDC-907 at the end of March. Aurigene (the company that created CA-170) has started a Phase 2 trial in multiple centers in India. Curis Stock Gaps Up On Today's Open (CRIS) - Stock Market ... Mar 21, 2011 · Shares of Curis (Nasdaq:CRIS) were gapping up Monday morning with an open price 12.6% higher than Friday's closing price. The stock closed at … CRIS Stock Quote of Curis Inc - InvestorPlace
Mar 31, 2020 · View today's stock price, news and analysis for Curis Inc. (CRIS). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. CURIS Stock Quote - Stock Price Today CURIS stock quote, chart and news. Get 's stock price today. Curis Stock Quote. CRIS - Stock Price, News, Charts ... Curis stock quote and CRIS charts. Latest stock price today and the US's most active stock market forums. CRIS Curis Inc. — Stock Price and Discussion | Stocktwits Apr 03, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.